Table 4.
Incidence of acute rejection (AR) at 3 and 12 months
| |
Oral ganciclovir |
Valganciclovir |
p-value |
|---|---|---|---|
| 3 months (n = 37) | 3 months (n = 51) | ||
| CAR scorea, median (quartiles) |
|
|
|
| 3 months |
2 (0 – 4) |
0 (0 – 2) |
0.02 |
| 12 months |
3 (2 – 6) |
1.5 (0 – 3) |
0.002 |
| CAR score/TBBb, median (quartiles) |
|
|
|
| 3 months |
0.5 (0 - 1) |
0 (0 - 0.5) |
0.008 |
| 12 months |
0.43 (0.2-0.67) |
0.14 (0-0.5) |
0.001 |
| At least one episode of AR grade ≥ 1, % (n) |
|
|
|
| 3 months |
68% (25/37) |
44% (20/45) |
0.03 |
| 12 months |
84% (31/37) |
62% (28/45) |
0.02 |
| At least one episode of AR grade ≥ 2, % (n) |
|
|
|
| 3 months |
51% (19/37) |
29% (13/45) |
0.04 |
| 12 months |
73% (27/37) |
49% (22/45) |
0.03 |
| At least two episodes of AR grade ≥ 2, % (n) |
|
|
|
| 3 months |
24% (9/37) |
13% (6/45) |
n.s |
| 12 months |
41% (15/37) |
20% (9/45) |
0.04 |
| Number of TBB, median (quartiles) |
|
|
|
| 3 months |
4 (3 – 4) |
4 (3 – 4) |
n.s |
| 12 months | 9 (8 – 9) | 8 (6 – 8) | 0.001 |
aCumulative acute rejection score (CAR score) varied between 0 and 6 at 3 months and between 0 and 16 at 12 months.
bCumulative acute rejection score (CAR score) divided by the number of evaluable transbronchial biopsies (TBB).